Recent life science studies have proposed that aberrant PI3K/AKT/mTOR signaling pathway activation is the key to the shortened life cycle of cancer patients and that aberrant activation of this pathway is a vital mechanism of resistance to targeted therapies (Droog et al., 2013). This evidence concerns the gene AKT1 and cancer.